A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321. (Q34514603)

2 August 2017

A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321. (English)

1 reference

2 August 2017

1 reference

Sylvie Fougeray

1

1 reference

2 August 2017

Chrystelle Brignone

series ordinal

2

1 reference

2 August 2017

Frédéric Triebel

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

31 March 2006

1 reference

2 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

2 August 2017

24

1 reference

2 August 2017

5426-5433

1 reference

2 August 2017

26

1 reference

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.050

10.1016/J.VACCINE.2006.03.050

7 January 2021

Identifiers

DOI

1 reference

release_mfjutrzphzeqvgqxoerkd6ybta

2 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mfjutrzphzeqvgqxoerkd6ybta

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference